Breast Cancer
« Previous EntriesAdherence to hormonal therapy for breast cancer needs improvement
Wednesday, July 14th, 2010Source: MedWire News
A large study of US women with early-stage breast cancer has revealed that fewer than half complete their regimen of hormone therapy according to the prescribed schedule, with younger women particularly likely to discontinue treatment.
To provide a more comprehensive understanding of the patient and clinical factors associated with discontinuation and nonadherence to hormonal […]
Breast cancer experts release guidelines on use of aromatase inhibitors
Tuesday, July 13th, 2010Source: Los Angeles Times
More than 100,000 women each year are diagnosed with a type of breast cancer called postmenopausal estrogen receptor-positive — the most common type of breast cancer. Studies in recent years have shown that an important tool to prevent recurrence of this type of breast cancer lies in the use of medications called […]
Bisphosphonates may cut breast cancer risk in postmenopausal women.
Friday, December 11th, 2009NBC Nightly News (12/10, story 4, 2:05, Williams) reported that “a new study that shows a drug a lot of older women already take to protect against bone loss, might also help protect against breast cancer.” NBC (Bazell) added, “At a major meeting of breast cancer researchers in San Antonio, the scientists today released the […]
Novartis drug Femara is superior to tamoxifen
Friday, August 21st, 2009Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara (letrozole) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive).
The data include an analysis from the Breast International Group (BIG) 1-98 trial that evaluated patients taking either a […]
Adjuvant aromatase inhibitors may lead to lower risk of recurrence than tamoxifen in breast cancer patients, researchers say.
Monday, December 15th, 2008Adjuvant aromatase inhibitors may lead to lower risk of recurrence than tamoxifen in breast cancer patients, researchers say.
MedPage Today (12/12, Phend) reported, “Whether breast cancer patients start on adjuvant aromatase inhibitors, or switch to them later, they lead to a lower risk of recurrence than tamoxifen, and, for some, better survival,” according to research presented […]
